| |
|
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir
and rilpivirine in both female and male genital fluids from HIV-positive
patients receiving regimens containing these antiretrovirals.
Lê MP, Belarbi L, Chaix ML, Dulioust E, et al
J Antimicrob Chemother. 2017 Sep
8.
Abstract
Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil
Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell
Proliferation In Vivo and In Vitro.
Xu P, Wang Y, Qin Z, Qiu L,
J Neuroimmune Pharmacol.
2017 Jul 22.
Abstract
Randomized controlled trial of the tolerability and completion of
maraviroc compared with Kaletra® in combination with Truvada® for HIV
post-exposure prophylaxis (MiPEP Trial).
Milinkovic A, Benn P, Arenas-Pinto A, et al
J Antimicrob Chemother. 2017 Mar 20.
Abstract
A randomized controlled clinical trial on the impact of CCR5
blockade with maraviroc in early infection on T-cell dynamics.
Karris MY, Umlauf A, Vaida F,
Medicine
(Baltimore). 2016 Nov;95(44):e5315.
Abstract
FULL-TEXT ARTICLE
Frequency and
Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive
subjects that display incomplete inhibition by maraviroc.
Borm K, Jakobsen MR, Cashin K, et
al
Retrovirology.
2016 Nov 3;13(1):74.
Paper
Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in
the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
Minami R, Takahama S, Kaku Y, Yamamoto M.
J Infect Chemother. 2016 Oct 8.
Abstract
FULL-TEXT ARTICLE
Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock.
Liu FC, Zheng CW, Yu HP.
Biomed Res Int. 2016;2016:5302069.
Paper
FULL-TEXT ARTICLE
Pharmacodynamic correlations using fresh and cryopreserved tissue following use
of vaginal rings containing dapivirine and/or maraviroc in a randomized,
placebo controlled trial.
Dezzutti CS, Richardson-Harman N, Rohan LC,
et al
Medicine
(Baltimore). 2016 Jul;95(28):e4174.
Paper
Single oral dose of maraviroc does not prevent ex-vivo HIV
infection of rectal mucosa in HIV-1 negative human volunteers.
Coll J, Moltó J, Boix J, Gómez-Mora E,
et al
AIDS. 2015 Oct
23;29(16):2149-2154.
Abstract
Reduced baseline sensitivity to Maraviroc inhibition among R5
HIV-1 isolates from individuals with severe immunodeficiency.
Karlsson U, Repits J, Antonsson L, et al
J Acquir Immune Defic Syndr. 2015 Oct
21.
Abstract
Missing CD4+ cell response in randomized clinical trials of
maraviroc and dolutegravir.
Cuffe R, Barnett C, Granier C, et al
HIV Clin Trials.
2015 Sep 12:
Abstract
An expedient synthesis of maraviroc (UK-427,857) <i>via</i> C-H
functionalization.
Bedell TA, Hone GA, Bois JD, Sorensen EJ.
Tetrahedron Lett. 2015 Jun
3;56(23):3620-3623.|||
Abstract
Preclinical discovery and development of maraviroc for the treatment of HIV.
Veljkovic N, Vucicevic J, Tassini S,
et al
Expert Opin Drug Discov. 2015
Jun;10(6):671-84
Abstract
FULL-TEXT ARTICLE
Parameters
Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome
in Patients on Maraviroc.
Sierra S, Dybowski JN, Pironti A, et al
PLoS One. 2015 May 13;10(5):e0125502
Paper
Safety, efficacy and indications of prescription of maraviroc in clinical
practice: Factors associated with clinical outcomes.
Llibre JM, Rivero A, Rojas JF, et al
Antiviral Res. 2015 May 12.
Abstract
Plasma concentrations of maraviroc and raltegravir after dual therapy in
patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
Lê MP, Soulié C, Assoumou L, et al.
J Antimicrob Chemother.
2015 Apr 26.
Abstract
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from
the phase IIb study A4001029.
Surdo M, Alteri C, Puertas MC, et al
Clin Microbiol Infect.
2015 Jan;21(1):103.e1-6
Abstract
Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5
antagonist Maraviroc.
Latinovic O, Schneider K, Szmacinski H, et al
Antiviral Res. 2014 Dec;112:80-90.
Abstract
Chemokine Receptor CCR5 Antagonist Maraviroc: Medicinal Chemistry and Clinical
Applications.
Xu GG, Guo J, Wu Y.
et al
Curr Top Med Chem.
2014;14(13):1504-14.
Abstract
Cytochrome P450 3A5 Genotype Impacts Maraviroc Concentrations in Healthy
Volunteers.
Lu Y, Fuchs EJ, Hendrix CW, Bumpus NN.
Drug Metab Dispos. 2014 Aug 12.
Abstract
Maraviroc reduces Regulatory T cells in ART-naive HIV-infected
subjects.
Pozo-Balado MM, Martínez-Bonet M, et al
J Infect Dis. 20
Abstract
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric
Cancer Cell Dissemination.
Mencarelli A, Graziosi L, Renga B,
et AL
Transl Oncol. 2013 Dec
1;6(6):784-93.
Abstract
Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor
Maraviroc Complex.
Tan Q, Zhu Y, Li J, et al
Science. 2013 Sep 12.
Abstract
Synergistic activity of carbosilane dendrimers in combination
with maraviroc against HIV in vitro.
Córdoba EV, Arnáiz E, De La Mata FJ,
et al
AIDS. 2013 Apr 22
Abstract
Maraviroc reduces cytokine expression and secretion in human
adipose cells without altering adipogenic differentiation.
Díaz-Delfín J, Domingo P, Giralt M, Villarroya F.
Cytokine. 2013 Mar;61(3):808-15.
Abstract |
HIV-1 dynamics and co-receptor usage in patients with ongoing
replication on MVC-containing regimens
Recordon-Pinson P, Raymond S, Bellecave P, et al
Antimicrob Agents Chemother.
2012 Dec 3
Abstract
Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism
of the Anti-HIV Drug Maraviroc.
Lu Y, Hendrix CW, Bumpus NN.
Drug Metab Dispos.
2012 Aug 24
Abstract |
FULL-TEXT ARTICLE
Levels of Soluble Endothelial Protein C Receptor Are Associated with
CD4(+) Changes in Maraviroc-Treated
HIV-Infected Patients.
Nozza S, Pogliaghi M, Chiappetta S, Spagnuolo V,
et al
PLoS One.
2012;7(6):e37032.
Paper |
Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific
Redistribution
Effect that Results in Increased Extracellular Viral Load.
Kramer VG, Schader SM, Oliveira M,
et al
Antimicrob Agents Chemother.
2012 May 21
Abstract
V3 determinants of HIV-1 escape from the CCR5
inhibitors Maraviroc and Vicriviroc.
Berro R, Klasse PJ, Moore JP, Sanders RW.
Virology. 2012 Mar 15.
Abstract |
Lower than expected maraviroc concentrations in cerebrospinal fluid
exceed the wild-type
CCR5-tropic HIV-1 50% inhibitory concentration.
Croteau D, Best BM, Letendre S, et al
AIDS. 2012 Feb 4.
Abstract
Antiviral effect of maraviroc in semen: a case report.
Pasquier C, Moinard N, Sauné K, et al
Antivir Ther. 2012 Feb 1.
Abstract
Novel agents for the treatment of HIV-2 infection.
Peterson K, Rowland-Jones S.
Antivir Ther. 2012 Jan 25.
Abstract
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate
efficacy in the treatment of patients with
rheumatoid arthritis in a randomized, double-blind placebo-controlled
trial.
Fleishaker DL, Garcia Meijide JA,
et
al
Arthritis Res Ther. 2012 Jan
17;14(1):R11.
Abstract |
Modulatory effects of the CCR5 antagonist maraviroc on
microglial pro-inflammatory activation
elicited by gp120.
Lisi L, Tramutola A, De Luca A,
et al
J Neurochem.
2011 Oct 21
Abstract
|
Rescue of HIV-1 long-time archived X4 strains to escape
maraviroc.
Baatz F, Struck D, Lemaire M, De Landtsheer S,
et al
Antiviral Res.
2011 Oct 13
Abstract |
Non-aqueous silicone elastomer gels as a
vaginal microbicide delivery system for the HIV-1 entry inhibitor
maraviroc.
Forbes CJ, Lowry D, Geer L,
et
al
J Control Release.
2011 Aug 12.
Abstract
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist
maraviroc on chemotactic activity of monocytes,
macrophages and dendritic cells.
Rossi R, Lichtner M, De Rosa A,
et al
Clin Exp Immunol. 2011
Nov;166(2):184-90.
Abstract
Allosteric Model of Maraviroc Binding to CC Chemokine
Receptor 5 (CCR5).
Garcia-Perez J, Rueda P, Alcami J,
et
al
J Biol Chem.
2011 Sep 23;286(38):33409-21.
Abstract
Lessons from maraviroc clinical trials.
Troia-Cancio P, Asmuth DM.
Expert Rev Anti Infect Ther.
2011 Jun;9(6):649-51
Abstract
Pharmacological Modulation of Chemokine Receptor
Function.
Scholten D, Canals M, Maussang D, et al
B
r J Pharmacol.
2011 Jun 23
Abstract
HIV-1 Dual/Mixed Tropic Isolates Show Different Genetic and Phenotypic
Characteristics
and Response to Maraviroc In Vitro.
Svicher V, Balestra E, Cento V, et al
Antiviral Res.
2011 Feb 21.
Abstract
HIV-1 escape from the CCR5 antagonist maraviroc associated with an
altered and less efficient mechanism
of gp120-CCR5 engagement that attenuates macrophage-tropism.
Roche M, Jakobsen MR, Sterjovski J,
J Virol. 2011 Feb
23.
Abstract
FULL-TEXT ARTICLE
Deep
sequencing to infer HIV-1 co-receptor usage: application to three
clinical trials of maraviroc in treatment-experienced patients.
Swenson LC, Mo T, Dong WW,
et
al
J Infect Dis.
2011 Jan 15;203(2):237-45
Paper
FULL-TEXT ARTICLE
Comparison of phenotypic and genotypic tropism determination in
triple-class-experienced HIV patients
eligible for maraviroc treatment.
Vandekerckhove L, Verhofstede C, Demecheleer E, et al
J Antimicrob Chemother.
2010 Dec 31
Paper
FULL-TEXT ARTICLE
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and
maraviroc protects against HIV-1 vaginal transmission
in a humanized mouse model.
Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R.
PLoS One. 2010 Dec
21;5(12):e15257
Paper
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma
concentrations are influenced by SLCO1B1 521 T>C
polymorphism.
Siccardi M, D'Avolio A, Nozza S, et al
Pharmacogenet Genomics.
2010 Dec;20(12):759-65.
Abstract
Maraviroc does not affect humoral response to the pandemic influenza
A-H1N1v 2009
adjuvanted vaccine in HIV-1-infected patients.
Canestri A, Krivine A, Assoumou L, et al
AIDS. 2010
Oct 19
Abstract |
FULL-TEXT ARTICLE
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and
Inflammation
and Associations with CD4 Cell Rises in HIV-Infected Patients.
Funderburg N, Kalinowska M, Eason J, et al
PLoS One. 2010 Oct 6;5(10). pii:
e13188.
Paper |
Hepatic safety and tolerability in the maraviroc
clinical development program.
Ayoub A, Alston S, Goodrich J, et al
AIDS. 2010
Oct 7.
Abstract |
Anti-Inflammatory Effect of Maraviroc in an HIV-Infected Patient With
Concomitant Myositis:
A Case Report.
Capetti AF, Pocaterra D, Zucchi P
J
Int Assoc Physicians AIDS Care 2010 Jul-Aug;9(4):201-2.|
Abstract |
Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected
Patients.
Tiraboschi JM, Niubo J, Curto J, Podzamczer D.
J Acquir Immune Defic Syndr.
2010 Aug 11
Abstract |
Maraviroc: a review of its use in the management of
CCR5-tropic HIV-1 infection.
Perry CM.
Drugs.
2010
Jun 18;70(9):1189-213
Abstract |
When and how to use maraviroc in HIV-infected patients.
Soriano V, Perno CF, Kaiser R, et al
AIDS. 2009 Oct 14
Abstract |
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract |
Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of
HIV-Negative
Women.
Dumond JB, Patterson KB, Pecha AL, et al
J Acquir Immune Defic Syndr. 2009 Jun 19
Abstract
|
A Double-Blind, Placebo-Controlled Trial of Maraviroc in
Treatment-Experienced Patients Infected with Non-R5 HIV-1.
Saag M, Goodrich J, Fätkenheuer
G, Clotet B,
et al
J Infect Dis.
2009 Jun 1;199(11):1638-1647
Abstract |
Maraviroc: A coreceptor CCR5 antagonist for management of HIV
infection.
Yost R, Pasquale TR, Sahloff EG.
Am J Health Syst Pharm.
2009 Apr 15;66(8):715-26
Abstract
|
Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human
Immunodeficiency
Virus Type 1.
Hunt JS, Romanelli F.
Pharmacotherapy.
2009 Mar;29(3):295-304
Abstract
|
Maraviroc: integration of a new antiretroviral drug class into clinical
practice.
Vandekerckhove L, Verhofstede C, Vogelaers D.
J Antimicrob Chemother. 2008
Apr 9
Abstract
Effect of single doses of maraviroc on the QT/QTc interval in healthy
subjects.
Davis JD, Hackman F, Layton G, et al
Br
J Clin Pharmacol. 2008 Apr;65 Suppl 1:68-75
New approaches in the treatment of HIV/AIDS - focus on maraviroc and
other CCR5 antagonists.
Schlecht HP, Schellhorn S, Dezube BJ, Jacobson JM.
Ther Clin Risk Manag. 2008 Apr;4(2):473-85.
Abstract
|
A receptor theory-based semimechanistic PD model for the CCR5
noncompetitive antagonist
maraviroc.
Jacqmin P, McFadyen L, Wade JR.
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:95-106.
Abstract
|
Maraviroc.
Fadel H, Temesgen Z.
Drugs Today (Barc). 2007 Nov;43(11):749-58.
Abstract
|
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency
virus (HIV)-1.
Ndegwa S.
Issues Emerg Health Technol. 2007 Dec;(110):1-8.
Abstract
|
Maraviroc, a chemokine CCR5 receptor antagonist for the
treatment of HIV infection
and AIDS.
Meanwell NA, Kadow JF.
Curr Opin Investig Drugs.
2007 Aug;8(8):669-81.
Abstract
|
Access denied? The status of co-receptor inhibition to counter
HIV entry.
Biswas P, Tambussi G, Lazzarin A
Expert Opin Pharmacother. 2007 May;8(7):923-33.
Abstract
|
Assessing theoretical risk and benefit suggested by genetic association
studies of CCR5:
experience in a drug development programme for maraviroc.
Wheeler J, McHale M, Jackson V, Penny M.
Antivir Ther. 2007;12(2):233-45.
Abstract
|
FULL TEXT
ARTICLE
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1)
variants in a minority
of HIV-1-infected patients following treatment with the CCR5
antagonist maraviroc is from a
pretreatment CXCR4-using virus reservoir.
Westby M, Lewis M, Whitcomb J, et al
J Virol. 2006
May;80(10):4909-20.
Paper
|
FULL TEXT ARTICLE
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective
small-molecule inhibitor of
chemokine receptor CCR5 with broad-spectrum anti-human
immunodeficiency virus
type 1 activity.
Dorr P, Westby M, Dobbs S, et al
Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32.
Paper
|
| |
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or
B virus: 144-week results from a randomized, placebo-controlled trial.
Rockstroh JK, Plonski F, Bansal M, et al
Antivir Ther. 2016 Dec 7.
Abstract
Hepatic safety of maraviroc in HIV-1-infected patients with
hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
Crespo M, Navarro J, Moreno S,
et
al
Enferm Infecc Microbiol Clin.
2016 Apr 6.
Abstract
Five-Year Safety Evaluation of Maraviroc in HIV-1-Infected
Treatment-Experienced Patients.
Gulick RM, Fatkenheuer G, Burnside R, et al
J Acquir Immune Defic Syndr.
2014 Jan 1;65(1):78-81.
Abstract
Safety and Immunovirologic Outcomes With Maraviroc
Combination Regimens in Patients With a History of Past Treatment Failures
and Virologic Resistance in Brazil:
An Open Label, Multicenter Phase 3b
Study.
Furtado JJ, Madruga JV, Bicudo EL, et al
AIDS Res Hum Retroviruses. 2013 Jun 3.
Abstract
Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and
Hepatitis B or C Included in the
Maraviroc Expanded Access Program.
Lazzarin A, Than S, Valluri SR, et al
HIV Clin Trials. 2012
Mar-Apr;13(2):83-9
Abstract
Drug safety evaluation of maraviroc for the treatment
of HIV infection.
Wasmuth JC, Rockstroh JK, Hardy WD
Expert Opin Drug Saf.
2011 Nov 26
Abstract
Hepatic safety and tolerability in the maraviroc clinical
development program.
Ayoub A, Alston S, Goodrich J, et al
AIDS. 2010 Nov 13;24(17):2743-50.
Abstract |
| |
|
Pharmacokinetics of Maraviroc, Raltegravir,
Darunavir, and Etravirine in the Semen of HIV-Infected Men.
Antoniou T, Hasan S, Loutfy MR, et al
J Acquir Immune Defic Syndr.
2013 Feb 1;62(2):e58-60.
Abstract
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with
800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside
analogues, in HIV-infected subjects.
Mora-Peris B, Croucher A, Else LJ, et al
J Antimicrob Chemother.
2013 Jan 30
Abstract
Pharmacokinetic profile of maraviroc 150 mg
dosed with darunavir/ritonavir once daily, with and without
nucleoside analogues, in HIV-infected subjects.
Mora-Peris B, Croucher A, Else L, et al
Int AIDS Soc. 2012 Nov
11;15(6):18332.
Abstract |
Pharmacokinetic Effects of Co-Administration of Lersivirine with Raltegravir or
Maraviroc
in Healthy Subjects.
Vourvahis M, Langdon G, Labadie RR, et al
Antimicrob Agents Chemother. 2011 Nov 28
Abstract
Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and
Rectal Tissue of
Healthy HIV-negative Men.
Brown KC, Patterson KB, Malone SA,
et
al
J Infect Dis.
2011 May;203(10):1484-90
Abstract
The use of the SAEM algorithm in MONOLIX software for estimation of
population pharmacokinetic-pharmacodynamic-viral
dynamics parameters
of maraviroc in asymptomatic HIV subjects.
Chan PL, Jacqmin P, Lavielle M,
et al
J Pharmacokinet Pharmacodyn.
2010 Nov 19
Abstract |
Assessment of the pharmacokinetics of co-administered
maraviroc and raltegravir.
Andrews E, Glue P, Fang J,
et al
Br J Clin Pharmacol.
2010 Jan;69(1):51-57.
Abstract |
Pharmacokinetics, safety and tolerability of a single oral
dose of maraviroc in HIV-negative
subjects with mild and moderate hepatic impairment.
Abel S, Davis JD, Ridgway CE, et al
Antivir Ther.
2009;14(6):831-7
Abstract
|
Maraviroc: pharmacokinetics and drug interactions.
Abel S, Back DJ, Vourvahis M.
Antivir Ther.
2009;14(5):607-18.
Abstract
|
A pharmacokinetic-pharmacodynamic model to optimize the phase
IIa development program of
maraviroc.
Rosario MC, Poland B, Sullivan J, et al
J Acquir Immune Defic Syndr. 2006 Jun;42(2):183-91.
Abstract |
| |
Lack of a significant pharmacokinetic interaction between maraviroc and
tacrolimus in allogeneic HSCT recipients.
Ganetsky A, Miano TA, Hughes ME,
et al
J Antimicrob Chemother.
2015 Apr 16.
Abstract
Pharmacokinetic Interaction between Maraviroc and
Fosamprenavir-Ritonavir: an Open-Label, Fixed-Sequence Study in Healthy
Subjects.
Vourvahis M, Plotka A, Mendes da Costa L, et al
Antimicrob Agents Chemother. 2013
Dec;57(12):6158-64.
Abstract
Interactions between Alcohol and the HIV Entry Inhibitor
Maraviroc.
Gruber VA, Rainey PM, Lum PJ,
et al
J Int Assoc Provid AIDS Care. 2013 Jul 23
Abstract
Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected
with HIV and hepatitis B virus following hepatic transplant due to
hepatocellular carcinoma.
Dufty NE, Gilleran G, Hawkins D,
et al
J Antimicrob Chemother.
2012 Dec 18.
Abstract
Pharmacokinetic interaction between maraviroc and etravirine
in HIV-infected patients receiving regimens
containing both drugs and no ritonavir-boosted protease
inhibitor.
Lê MP, Solas C, Garraffo R, Gagnieu MC,
et al
J Antimicrob Chemother.
2012 Jul 6.
Abstract |
Pharmacokinetic Effects of Co-Administration of Lersivirine with Raltegravir or
Maraviroc
in Healthy Subjects.
Vourvahis M, Langdon G, Labadie RR, et al
Antimicrob Agents Chemother. 2011 Nov 28
Abstract
Synergistic activity profile of griffithsin in combination with
tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Férir G, Palmer KE, Schols D.
Virology.
2011 Jul 27
Abstract
Pharmacokinetic interaction of
ritonavir-boosted elvitegravir and maraviroc.
Ramanathan S, Abel S, Tweedy S,
et al
J Acquir Immune Defic Syndr.
2010 Feb 1;53(2):209-14.
Abstract |
Assessment of the pharmacokinetics of co-administered
maraviroc and raltegravir.
Andrews E, Glue P, Fang J,
et al
Br J Clin Pharmacol.
2010 Jan;69(1):51-57.
Abstract |
|
|
|
| |
Reduced Frequencies and Activation of Regulatory T Cells
After the Treatment of HIV-1-Infected Individuals with the CCR5
Antagonist Maraviroc Are Associated with a Reduction in Viral Loads
Rather Than a Direct Effect of the Drug on Regulatory T Cells.
Joedicke JJ, Dirks M, Esser S, et al
Viral Immunol.
2016 Apr;29(3):192-6.
Abstract
HIV-1 adaptation to low levels of CCR5 results in V3 and
V2 loop changes that increase envelope pathogenicity, CCR5 affinity and
decrease susceptibility to Maraviroc.
Garg H, Lee RT, Maurer-Stroh S, Joshi A.
Virology. 2016 Mar 24;493:86-99
Abstract
Virological response to short-course maraviroc
monotherapy does not predict viral tropism in HIV-1-infected
treatment-naive patients.
Hernández-Novoa B, Madrid-Elena N,
et
al
J Antimicrob Chemother. 2014 Mar
12
.Abstract
Innate immunity cell activation in virologically
suppressed HIV-infected maraviroc-treated patients.
Dentone C, Di Biagio A, Parodi A, et al
AIDS. 2014 Feb 4
Abstract
Virologic Response, Early HIV-1 Decay and Maraviroc
Pharmacokinetics with the Nucleos(t)ide-free Regimen of Maraviroc plus
Darunavir/ritonavir in a Pilot Study.
Taiwo B, Acosta EP, Ryscavage P, et al
J Acquir Immune Defic Syndr. 2013 Jun
21
Abstract
Use of Cellular HIV DNA to Predict Virologic Response to
Maraviroc: Performance of Population-based and Deep Sequencing.
Swenson LC, Dong WW, Mo T, et al
Clin Infect Dis.
2013
Feb 21
Abstract |
|
Population-Based Sequencing of the V3-loop Can Predict the
Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT
Trial.
McGovern RA, Thielen A, Portsmouth S, et al
J Acquir Immune Defic Syndr.
2012 Nov 1;61(3):279-86
Abstract
Population-based Sequencing of the V3-loop can Predict the
Virological Response to Maraviroc in Treatment-naïve Patients of the MERIT
Trial.
McGovern RA, Thielen A, Portsmouth S, et al
J Acquir Immune Defic Syndr. 2012 Jul
11.
Abstract
Correlation of the virological response to short-term Maraviroc monotherapy
with standard and
deep sequencing-based genotypic tropism methods.
Gonzalez-Serna A, McGovern RA, Harrigan PR,
et al
Antimicrob Agents Chemother. 2011 Dec
5
Abstract |
Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected
Patients:
Frequency of Subjects with Virological Response and Associated Factors.
Ruiz-Mateos E, González-Serna A, et al
Antimicrob Agents Chemother. 2011
Oct;55(10):4664-9.
Abstract
FULL-TEXT PDF ARTICLE
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a
phenotypic assay
and correlation with the virological response to maraviroc: the ANRS
GenoTropism study.
Recordon-Pinson P, Soulié C, et al
Antimicrob Agents Chemother.
2010 Jun 7.
Paper |
| |
Effects of treatment with Maraviroc a CCR5 inhibitor on a
human hepatic stellate cell line.
Coppola N, Perna A, Lucariello A,
et al
J Cell Physiol.
2018 Jan
Abstract
Immunologic Effects of Maraviroc in HIV-Infected
Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A
Sub-Study of the CADIRIS Trial.
Belaunzarán-Zamudio PF, Azzoni L, Canaday DH, et al
Pathog Immun.
2017;2(2):151-177.
Effects
of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV
Co-infected Patients.
Maggi P, Bruno G, Perilli F,
et al
In
Vivo. 2017
01-02;31(1):125-131.
Abstract
Effectiveness, safety, durability and immune recovery in a
retrospective, multicentre, observational cohort of ART-experienced,
HIV-1-infected patients receiving maraviroc.
Dentone C, Sterrantino G, Signori A,
et al
Int J STD AIDS.
2017 Jan q
Abstract
Genotypic tropism testing of proviral DNA to guide maraviroc
initiation in aviraemic subjects: 48-week analysis of results from the
PROTEST study.
Poveda E, Hernández-Quero J, Pérez-Elías MJ,
et al
HIV Med. 2016 Dec
30.
Abstract
Lack of effect of Maraviroc intensification on blood and gut reservoir.
Tiraboschi J, Ray S, Patel K, Pace M, et al
AIDS Res Hum Retroviruses.
2016 Dec 4
Abstract
Maraviroc in addition to cART during primary HIV infection: Results from
MAIN randomized clinical trial and 96-weeks follow-up.
Ripa M, Pogliaghi M, Chiappetta S,
J Clin Virol. 2016 Oct
31;85:86-89
Abstract
Immunovirological
Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48
Weeks in Naive HIV-Infected Patients.
Pulido I, Genebat M, Alvarez-Rios AI,
et al
Viral Immunol.
2016 Oct;29(8):471-477.
Abstract
48 week outcomes of maraviroc-containing regimens following
the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.
Nozza S, Pignataro AR, Galli L,
et al
New Microbiol.
2016 Sep;39(3):192-6.
Abstract
Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated
Patients, an Open-Label Randomized Cross-Over Pilot Study.
Krikke M, Tesselaar K, Arends JE,
et al
Infect Dis Ther.
2016 Jun 14
Abstract
Neurocognition in maraviroc- compared to tenofovir: a double
blind randomized placebo controlled trial ACTG A5303.
Robertson KR, Miyahara S, Lee A,
et al
AIDS. 2016 Jun 20
Abstract
Differential CD4 count increase and CD4: CD8 ratio normalization with
maraviroc compared to tenofovir: a randomized trial.
Chan ES, Landay AL, Brown TT,
et al
AIDS.
2016 Jun 8.
Abstract
Maraviroc Once DailyExperience in Routine Clinical Practice
Saumoy M, Llibre JM, Terrón A,
AIDS
Res Hum Retroviruses.
2016 Jun 1.
Abstract
A randomized clinical trial comparing ritonavir-boosted
lopinavir versus maraviroc each with tenofovir plus emtricitabine for
post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B
J Antimicrob Chemother.
2016 Mar 18.
Abstract
Once-daily maraviroc versus tenofovir/emtricitabine each
combined with darunavir/ritonavir for initial HIV-1 treatment: 48-week
results from the MODERN study.
Stellbrink HJ, Fevre EL, Carr A,
et al
AIDS. 2016 Feb 5
Abstract
Maraviroc: a review of its use in HIV infection and beyond.
Woollard SM, Kanmogne GD.
Drug Des Devel Ther. 2015 Oct
1;9:5447-68
Abstract
Safety, efficacy and indications of prescription of maraviroc
in clinical practice: Factors associated with clinical outcomes.
Llibre JM, Rivero A, Rojas JF,
et
al
Antiviral Res. 2015 Aug;120:79-84
Abstract
The Efficacy and Safety of Maraviroc Addition to a Stable
Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not
Influenced by Age.
Blanco JR, Arroyo-Manzano D, Rojas-Liévano JF, et al
AIDS Res Hum Retroviruses. 2015 Jun 15.
Abstract
FULL-TEXT ARTICLE
Maraviroc - A
CCR5 Antagonist for the Treatment of HIV-1 Infection.
Van Der Ryst E.
Front Immunol. 2015
Jun 5;6:277.
Paper
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse
transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week
final results of VEMAN study.
Nozza S, Galli L, Antinori A, Chiappetta S,
et akl
Clin Microbiol Infect.
2014 Dec 11
Abstract
FULL-TEXT ARTICLE
Maraviroc
Failed to Control Progressive Multifocal Leukoencephalopathy-Associated IRIS in
a Patient with Advanced HIV Infection.
Rodríguez M, Silva-Sánchez FA, Luna-Rivero C, et al
Case Rep Med.
2014;2014:381480
Paper
Safety and therapeutic efficacy of the switch to
maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results
from GUSTA study.
Gagliardini R, Rossetti B, Bianco C, et al
J Int AIDS Soc. 2014
Nov 2;17(4(Suppl 3)):19818.
Abstract
Monotherapy with darunavir/ritonavir is effective and safe in
clinical practice.
Pasquau J, López-Cortés L, Mayorga MI, et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl
3)):19813.
Abstract
Seminal pharmacokinetics and antiviral efficacy of once-daily
maraviroc plus lopinavir/ritonavir in HIV-infected patients.
Calcagno A, Nozza S, Simiele M,
et al
J Antimicrob Chemother. 2014 May 8.
Abstract
.
FULL-TEXT ARTICLE
Efficacy and
safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1:
5-year findings.
Cooper DA, Heera J, Ive P,
et al
AIDS. 2014 Mar
13;28(5):717-725.
Paper
Efficacy and safety of once-daily maraviroc plus
ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life
setting
Macías J, Recio E, Márquez M, García C, et al
HIV Med. 2014 Feb 24.
Abstract
.
Virological and immunological response to antiretroviral regimens containing
maraviroc in HIV-1-infected patients in clinical practice: role of different
tropism testing results and of concomitant treatments.
Rossetti B, Bianco C, Bellazzi LI,
et al
AIDS Res Hum Retroviruses. 2013 Aug 25.
Abstract
Assessment of Maraviroc Exposure-Response Relationship at 48
Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.
Jacqmin P, Wade JR, Weatherley B,
et al
CPT Pharmacometrics Syst Pharmacol. 2013 Aug
14;2:e64
Abstract
A phase 4, single-arm, open-label, pilot study of maraviroc,
raltegravir and darunavir/r in HIV-1 adults with triple class failure: TERCETO
study.
Patterson P, Magneres C, Sued O,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18268
Abstract
Use of maraviroc in clinical practice: a multicenter observational study.
Dentone C, Fraccaro P, Fenoglio D et al
J Int AIDS Soc.
2012 Nov 11;15(6):18265.
Abstract
Open-label study of maraviroc+lamivudine/zidovudine in
treatment-naïve adults infected with HIV-1, predominantly subtype A, by
population genotyping.
Portsmouth S, Valluri S, Craig C,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18261
Abstract
Maraviroc150 mg QD plus lopinavir/ritonavir, a
NRTI-sparing regimen for HIV-infected naïve patients: 48-weeks final results.
Nozza S, Galli L, Chiappetta S, Antinori A,
J Int AIDS Soc.
2012 Nov 11;15(6):18232.
Abstract
Maraviroc once daily nucleoside analog-sparing regimen in
treatment-naïve patients: randomized, openlabel pilot study.
Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, et al
J Acquir Immune Defic Syndr.
2012 Nov 26
Abstract
|
The MOTIVATE trials: maraviroc therapy in antiretroviral
treatment-experienced HIV-1-infected patients.
van Lelyveld SF, Wensing AM, Hoepelman AI.
Expert Rev Anti Infect Ther.
2012 Oct 31.
Abstract
|
Real-Life Outcomes of Maraviroc-Based Regimens in HIV-1-Infected
Individuals.
Eltahir Babiker ZO, Douthwaite ST,
et al
J Int Assoc Physicians AIDS Care (Chic).
2012 Oct 16.
Abstract
Effect of maraviroc on HIV-disease progression-related
biomarkers.
Romero-Sánchez MC, Machmach K, et al
Antimicrob Agents Chemother
2012 Sep 4.
Abstract
|
A pilot trial of adding maraviroc to suppressive antiretroviral
therapy for suboptimal CD4+ T-cell recovery
despite sustained virologic
suppression: ACTG A5256.
Wilkin TJ, Lalama CM, McKinnon J,et
al
J Infect Dis. 2012 Jun
27.
Abstract
Immune recovery and T cell subset analysis during effective
treatment with maraviroc.
Cossarini F, Galli A, Galli L, Bigoloni A, Salpietro S,
et al
J Antimicrob Chemother. 2012 Jun
Abstract
|
Impaired maraviroc and raltegravir clearance in a human
immunodeficiency virus-infected patient with end-stage liver
disease
and renal impairment: a management dilemma.
Pau AK, Penzak SR, Boyd SD, et al
Pharmacotherapy.
2012 Jan;32(1):
Abstract
|
Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing
Regimens (R+M+) versus
Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M-).
Antoniou T, Smith G, Su D, et al
J Int Assoc Physicians AIDS Care (Chic
Abstract
Once daily maraviroc 300 mg or 150 mg in combination
with ritonavir-boosted darunavir 800/100 mg.
Okoli C, Siccardi M, Thomas-William S,.et
al
J Antimicrob Chemother.
2011 Dec 15.
Abstract
Our experience with maraviroc treatment in HIV positive patients
Vondracková H, Stanková M, Machala L, et al
Cas Lek Cesk. 2011;150(8):447-50
Abstract
|
Deep V3 sequencing for HIV type 1 tropism in treatment-naive
patients: a reanalysis of the MERIT trial of maraviroc.
Swenson LC, Mo T, Dong WW, et al
Clin Infect Dis. 2011 Oct;53(7):732-42.
Abstract
Clinical Utility of Maraviroc.
Parra J, Portilla J, Pulido F,
et al
Clin Drug Investig. 2011
May 20.
Abstract
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in
primary cells: implications for treatment and prevention.
Latinovic O, Le N, Reitz M, Pal R,
et al
AIDS. 2011 Jun 1;25(9):1232-5.
Abstract
Use of Maraviroc-, Raltegravir-, and Etravirine-Containing Regimens in
Treatment-Experienced Patients:
A Case-Series Study.
Youngblood C, Sayana S, Khanlou H.
J Int Assoc Physicians AIDS Care (Chic).
2011 Mar 23
Abstract
Maraviroc first-line therapy for HIV infection. Too risky.
[No authors listed]
Prescrire Int. 2010
Nov;19(110):252-4.
Abstract
Two-Year Safety and Virologic Efficacy of Maraviroc in
Treatment-Experienced Patients
With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis
of MOTIVATE 1 and 2.
Hardy WD, Gulick RM, Mayer H, et al
J Acquir Immune Defic Syndr.
2010 Aug 11.
Abstract
|
Long-Term Immunovirogical Effect And
Tolerability Of A Maraviroc-Containing Regimen
In Routine Clinical Practice.
Genebat M, Ruiz-Mateos E, Pulido I, et al
Curr HIV Res. 2010 Jul 20
Abstract
|
Maraviroc-containing regimen suppresses HIV replication
in the cerebrospinal fluid of patients with neurological symptoms.
Melica G, Canestri A, Peytavin G, et al
AIDS.
2010 Jul 1
Abstract
|
Maraviroc versus Efavirenz, Both in Combination with
Zidovudine-Lamivudine, for the Treatment
of Antiretroviral-Naive
Subjects with CCR5-Tropic HIV-1 Infection.
Cooper DA, Heera J, Goodrich J, et al
J Infect Dis.
2010 Feb 12.
Abstract
|
Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist
Maraviroc.
Latinovic O, Kuruppu J, Davis C,
et al
Clin Med Ther. 2009;1:1497-1510
Abstract |
Impact of adding maraviroc to antiretroviral regimens in patients with full
viral suppression
but impaired CD4 recovery.
Stepanyuk O, Chiang TS, Dever LL, et al
AIDS. 2009 Jul 4
Abstract |
Maraviroc efficacy in clinical studies on the
development of the molecule
Moreno S, Hernández B, Gutiérrez C, Delsol E.
Enferm Infecc Microbiol Clin.
2008 Oct;26 Suppl 11:17-22.
Abstract |
|
|
|
| |
Development and validation of a liquid
chromatographic-tandem mass spectrometric method for the multiplexed
quantification of etravirine, maraviroc, raltegravir, and rilpivirine in
human plasma and tissue.
Parsons TL, Marzinke MA.
J Pharm Biomed Anal. 2016 Sep 4;131:333-344.
Abstract
Validation of the HIV Tropism Test TROCAI Using the
Virological Response to a Short-term Maraviroc Monotherapy Exposure.
Gonzalez-Serna A, Genebat M, De Luna-Romero M,
Antimicrob Agents Chemother.
2016 Aug 1.
Abstract
Maraviroc Clinical Test (MCT) as an alternative tool to
decide CCR5-antagonists prescription in naïve HIV-infected patients.
Genebat M, de Pablo-Bernal R, Pulido I, et al
Antiviral Res. 2015 Jun 26.
Abstract
FULL-TEXT ARTICLE
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and
Response to Maraviroc.
Rodriguez C, Soulié C, Marcelin AG, et
al
PLoS One. 2015 Jun
11;10(6):e0127816
Paper
Development and Bioanalytical Validation of a Liquid
Chromatographic-Tandem Mass Spectrometric (LC-MS/MS) Method for the
Quantification of the CCR5 Antagonist
Maraviroc in Human Plasma.
Emory JF, Seserko LA, Marzinke MA.
Clin Chim Acta. 2014 Feb 19.
Abstract
Use of Cellular HIV DNA to Predict Virologic Response to
Maraviroc: Performance of Population-based and Deep Sequencing.
Swenson LC, Dong WW, Mo T, et al
Clin Infect Dis. 2013
Feb 21
Abstract
Factors influencing the sensitivity and specificity of
conventional sequencing in Human Immunodeficiency Virus-1 tropism
testing.
Knapp DJ, McGovern RA, Dong W, et al
J Clin Microbiol.
2012 Nov 21.
Abstract
Test for CCR5 tropism and treatment with maraviroc in
Sicily: an observational retrospective multicentre study.
Celesia B, Gussio M, Franco A, et al
J Int AIDS Soc. 2012
Nov 11;15(6):18216
Abstract
Optimisation of baseline genotypic testing for safe and
efficient maraviroc administration.
Sierra S, Dybowski J, Pironti A, et al
J Int AIDS Soc.
2012 Nov 11;15(6):18134.
Abstract
Maraviroc Observational Study: The Impact of Expanded Resistance Testing
and Clinical Considerations
for Antiretroviral Regimen Selection in Treatment-Experienced Patients.
Willig JH, Wilkins SA, Tamhane A,
et al
AIDS Res Hum Retroviruses. 2012
Sep 6
Abstract
Alterations in cerebrospinal fluid chemokines are associated with
maraviroc exposure and in vivo metabolites measurable
by magnetic
resonance spectroscopy.
Vera JH, Garvey LJ, Allsop JM,
HIV Clin Trials.
2012 Jul-Aug;13(4):222-7.
Abstract
Baseline CD4(+) T-cell counts and weighted background susceptibility
scores strongly predict response
to maraviroc regimens in treatment-experienced patients.
Schapiro JM, Boucher CA, Kuritzkes DR, et al
Antivir Ther.
2011;16(3):395-404
Abstract
Discordance rates between Trofile test and short-term virological response to
maraviroc.
Genebat M, Ruiz-Mateos E, González-Serna A, et al
Antiviral Res. 2011
Feb;89(2):182-5.
Abstract
An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857)
in human plasma, urine and cerebrospinal fluid.
Brewer E, Felix T, Clarke P, et al
Biomed Chromatogr.
2010 Dec;24(12):1316-23.
Abstract |
FULL-TEXT PDF ARTICLE
Development and application of a simple LC-MS method for the
determination of plasma
maraviroc concentrations.
Takahashi M, Hirano A, Okubo N, et al
J Med Invest.
2010;57(3,4):245-250.
Paper |
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a
phenotypic assay
and correlation with the virological response to maraviroc: the ANRS
GenoTropism study.
Recordon-Pinson P, Soulié C, Flandre P, et al
Antimicrob Agents Chemother. 2010 Jun 7
Abstract |
A validated high-performance liquid chromatography-ultraviolet method for
quantification
of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.
D'Avolio A, Simiele M, Baietto L,
et al
Ther Drug Monit. 2010
Feb;32(1):86-92
Abstract |
|
|
|
| |
Analysis of clinical HIV-1 strains with resistance to
maraviroc reveals strain-specific resistance mutations, variable degrees of
resistance, and minimal cross-resistance to other CCR5 antagonists.
Flynn J, Ellenberg P, Duncan R, Ellett A, et al
AIDS Res Hum Retroviruses.
2017 Aug 11.
Abstract
Characterising the diverse mutational pathways associated with
R5-tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor.
Jiang X, Feyertag F, Meehan C, et al
J Virol. 2015 Sep 2. pii: JVI.01384-15.
Abstract
FULL-TEXT ARTICLE
Impact of maraviroc-resistant mutation M434I in the C4 region of HIV-1 gp120 on
sensitivity to antibody-mediated neutralization.
Boonchawalit S, Harada S, Shirai N,
et al"
Jpn J Infect Dis. 2015 Jul 10
Paper
.FULL-TEXT ARTICLE
A single-residue
change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5
binding affinity while increasing replicative capacity.
Garcia-Perez J, Staropoli I, Azoulay S, et al
Retrovirology. 2015 Jun
18;12:50.
Paper
Impact of Maraviroc-resistant and Low CCR5-adapted Mutations
Induced by in vitro Passage on Sensitivity to Anti-Env Neutralizing Antibodies.
Yoshimura K, Harada S, Boonchawalit S,
et al
J Gen Virol. 2014 May 2.
Abstract
Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be
predicted by the V3 sequence.
Delobel P, Cazabat M, Saliou A, et al
J Antimicrob Chemother.
2013 Jun 21.
Abstract |
Safety and Immunovirologic Outcomes With Maraviroc Combination
Regimens in Patients With a History of Past Treatment Failures and Virologic
Resistance in Brazil: An Open Label, Multicenter Phase 3b Study.
Furtado JJ, Madruga JV, Bicudo EL, et al
AIDS Res Hum Retroviruses. 2013 Jun 3.
Abstract
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist
maraviroc despite divergent resistance levels
and lack of common gp120
resistance mutations.
Roche M, Salimi H, Duncan R, Wilkinson BL, et al
Retrovirology.
2013 Apr 20;10(1):43.
Abstract |
Multifaceted mechanisms of HIV inhibition and
resistance to CCR5 inhibitors PSC-RANTES and Maraviroc
Lobritz MA, Ratcliff AN, Marozsan AJ, et al
Antimicrob Agents Chemother.
2013 Mar 25
Abstract
HIV-1 Resistance to Maraviroc Conferred by a
CD4 Binding Site Mutation in the Envelope Glycoprotein
gp120.
Ratcliff AN, Shi W, Arts EJ.
J Virol. 2013
Jan;87(2):923-34.
Abstract |
HIV-1 Resistance to Maraviroc Conferred by a
CD4 Binding Site Mutation in the Envelope Glycoprotein GP120.
Ratcliff AN, Shi W, Arts EJ.
J Virol.
2012 Nov 7.
Abstract |
FULL-TEXT ARTICLE
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and
other CCR5 antagonists in vitro has an inherent, low-level ability
to utilize MVC-bound CCR5 for entry
Roche M, Jakobsen MR, Ellett A,
et al
Retrovirology. 2011
Nov 7;8:89.
Paper
FULL-TEXT
ARTICLE
Resistance to the CCR5 Inhibitor 5P12-RANTES Requires a Difficult
Evolution from CCR5 to CXCR4 Coreceptor Use.
Nedellec R, Coetzer M, Lederman MM,
et al
PLoS One.
2011;6(7):e22020.
Paper
A combination of polymorphic mutations in V3 loop of
HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
Yuan Y, Maeda Y, Terasawa H,
et al
Virology.
2011 May 10;413(2):293-9.
Abstract
Evaluation of Primary Resistance to HIV Entry Inhibitors Among
Brazilian Patients Failing Reverse
Transcriptase/Protease Inhibitors Treatment Reveal High Prevalence
of Maraviroc Resistance-Related Mutations.
Alencar CS, Nishiya A, Ferreira S, et al
AIDS Res Hum Retroviruses.
2010 Oct 26.
Abstract |
A maraviroc-resistant HIV-1 with narrow cross-resistance to other
CCR5 antagonists depends
on both N-terminal and extracellular loop domains of drug-bound
CCR5.
Tilton JC, Wilen CB, Didigu CA, et al
J Virol. 2010
Aug 11.
Abstract |
|
|
| |
|
Less Bone Loss with Maraviroc- Compared to Tenofovir-Containing
Antiretroviral Therapy in the ACTG A5303 Study.
Taiwo BO, Chan ES, Fichtenbaum CJ,
et al
Clin Infect Dis. 2015 Jun 9.
Abstract
Potential anti-inflammatory effects of maraviroc in HIV-positive patients: A
pilot study of inflammation, endothelial dysfunction, and coagulation markers.
Francisci D, Falcinelli E, Baroncelli S, et al
Scand J Infect Dis.
2014 Jun;46(6):466-70
Abstract
FULL-TEXT ARTICLE
Maraviroc and JC virus-associated immune reconstitution inflammatory
syndrome.
Giacomini PS, Rozenberg A, Metz I, et al
N Engl J Med. 2014 Jan
30;370(5):486-8.
Paper
Maraviroc-induced decrease in
circulating bacterial products is not linked to an
increase in immune activation in HIV-infected
individuals.
Psomas C, Lavigne JP, Barbuat C, et al
Blood.
2013 Sep 26;122(13):2282-3.
Abstract
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a
pharmacokinetic and cerebral
metabolite study.
Garvey L, Nelson M, Latch N, et al
J Antimicrob Chemother.
2011 Oct 10
Abstract
|
|
| |
CSF inflammatory markers and neurocognitive function after
addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV
patients: the CINAMMON study.
Barber TJ, Imaz A, Boffito M,
et al
J Neurovirol. 2017 Dec
26.
Abstract
FULL-TEXT ARTICLE
Maraviroc in
PML-IRIS: A separate ball game under HIV infection and natalizumab?
Steiner I, Benninger F.
Neurol Neuroimmunol Neuroinflamm.
2017 Feb
Paper
FULL-TEXT ARTICLE
Maraviroc as possible treatment for PML-IRIS in natalizumab-treated
patients with MS.
Hodecker SC, Stürner KH, Becker V, et
a;
E
Neurol Neuroimmunol Neuroinflamm. 2017 Feb 8;4(2):e325.
Paper
FULL-TEXT ARTICLE
Severe early
natalizumab-associated PML in MS: Effective control of PML-IRIS with
maraviroc.
Bsteh G, Auer M, Iglseder S, Walchhofer LM,
et al
Neurol Neuroimmunol Neuroinflamm.
2017 Feb 8
Paper
FULL-TEXT ARTICLE
Strategic use of dual regimens of boosted protease inhibitors plus maraviroc
in poorly adherent subjects in view of long-acting drugs: A retrospective
study.
Capetti AF, Micale M, Carenzi L, et
al
Medicine (Baltimore). 2017 Feb
Paper
Maraviroc ameliorates the increased adipose tissue macrophage
recruitment induced by a high-fat diet in a mouse model of obesity.
Pérez-Matute P, Pichel JG, Iñiguez M,
et al
Antivir Ther.
2016 Oct 11.
Abstract
Immunovirological Efficacy of Once-Daily
Maraviroc Plus Ritonavir-Boosted Atazanavir After 48
Weeks in Naive HIV-Infected Patients.
Pulido I, Genebat M, Alvarez-Rios AI,
et al
Viral Immunol.
2016 Oct;29(8):471-477.
Abstract
Maraviroc/raltegravir simplification strategy following 6
months of quadruple therapy with
tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV
patients.
Pradat P, Durant J, Brochier C, Trabaud MA, et al
J Antimicrob Chemother.
2016 Jul 17.
Abstract
Pharmacodynamic correlations using fresh and cryopreserved
tissue following use of vaginal rings containing dapivirine and/or maraviroc
in a randomized, placebo controlled trial.
Dezzutti CS, Richardson-Harman N, Rohan LC,
et al
Medicine
(Baltimore).
2016 Jul;95(28):e4174.
Abstract
Factors associated with virological response to a switch regimen containing
maraviroc for antiretroviral-experienced HIV-1-infected patients.
Bocket L, Peytavin G, Alidjinou EK,
et al
J Antimicrob Chemother. 2016 May 2
Abstract
Maraviroc, as a switch option, in HIV-1 infected individuals with stable,
well-controlled HIV replication and R5-tropic virus on their first N(t)RTI+PI/r
regimen. Week 48 results of the randomised, multicentre MARaviroc switCH study
(MARCH).
Pett SL, Amin J, Horban A, et al
Clin
Infect Dis. 2016 Apr 5.
Abstract
Is there a role for maraviroc to treat HIV-associated central nervous system
white matter disease?
Ball C, Sudhanva M, Jarosz J, et al
AIDS.
2016 Jan;30(2):334-6
Abstract
Markers of HIV reservoir size and immune activation after treatment in acute HIV
infection with and without raltegravir and maraviroc intensification.
Ananworanich J, Chomont N, Fletcher JL,
et al
J Virus Erad.
2015;1(2):116-122.
Abstract
Virologic and immunologic effects of adding maraviroc to suppressive
antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR, Hilldorfer BB, Lalama CM, et al
AIDS. 2015 Oct
23;29(16):2121-2129.
Abstract
FULL-TEXT ARTICLE
Maraviroc Intensification of cART in Patients with Suboptimal Immunological
Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
van Lelyveld SF, Drylewicz J, Krikke M, et al
PLoS One. 2015 Jul
24;10(7):e0132430.
Paper
Clinical and immunologic effects of maraviroc in progressive
multifocal leukoencephalopathy.
Middel A, Arends JE, van Lelyveld SF, et
al
Neurology. 2015 Jun 3
Abstract
Ineffective central nervous system HIV suppression of once-a-day
maraviroc and ritonavir boosted darunavir dual therapy: four case
reports.
Ahmed N, Okoli C, Ainsworth J.
Int J STD AIDS. 2015 May 11
Abstract
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune
profile with low-level HIV viremia.
Campillo-Gimenez L, Assoumou L, Valantin MA, et al
AIDS. 2015 Feb 25
Abstract
FULL-TEC ARTICLE
Maraviroc Failed
to Control Progressive Multifocal Leukoencephalopathy-Associated IRIS in a
Patient with Advanced HIV Infection.
Rodríguez M, Silva-Sánchez FA, et al
Case
Rep Med. 2014;2014:381480.
Paper
Use of maraviroc in patients with undetectable viral load:
efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
Elías MJ, Arroyo D, Diaz A, Herrero C, et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19800.
Abstract
Bone mineral density improvement after 48 weeks of switch to
maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA
study.
Bianco C, Rossetti B, Gagliardini R, et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl
3)):19816.
Abstract
Treatment intensification with maraviroc (CCR5 antagonist) leads
to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected
subjects and is associated with improvements in neurocognitive test performance:
implications for HIV-associated neurocognitive disease (HAND).
Ndhlovu LC, Umaki T, Chew GM, et al
J Neurovirol. 2014 Sep 17.
Abstract
Maraviroc intensification in patients with suppressed HIV viremia
has limited effects on CD4+ T cell recovery and gene expression.
Beliakova-Bethell N, Jain S, et al
Antiviral Res.
2014 Apr 23.
Abstract
Four-year outcome of a PI and NRTI-sparing salvage regimen:
maraviroc, raltegravir, etravirine.
Nozza S, Galli L, Bigoloni A, Gianotti N,
et al
New Microbiol. 2014 Apr;37(2):145-51
Abstract
Maraviroc plus raltegravir failed to maintain virological
suppression in HIV-infected patients with lipohypertrophy: results from the
ROCnRAL ANRS 157 study.
Katlama C, Assoumou L, Valantin MA, et al
J Antimicrob Chemother.
2014 Feb 16.
Abstract
FULL-TEXT ARTICLE
Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in
Recently HIV-1-Infected Individuals.
Kawana-Tachikawa A, Llibre JM, Bravo I, et al
PLoS One. 2014 Jan 27;9(1):e87334.
Paper
FULL-TEXT ARTICLE
Maraviroc as Intensification Strategy in HIV-1 Positive Patients
with Deficient Immunological Response: an Italian Randomized
Clinical Trial.
Rusconi S, Vitiello P, Adorni F, et al
PLoS One. 2013
Nov 14;8(11):e80157
Paper
The immunologic effects of maraviroc intensification in
treated HIV-infected individuals with incomplete CD4+ T cell recovery:
a randomized trial.
Hunt PW, Shulman N, Hayes TL, et al
Blood. 2013 Apr 15
Abstract
Switching the third drug of antiretroviral therapy to
maraviroc in aviraemic subjects: a pilot, prospective, randomized
clinical trial.
Bonjoch A, Pou C, Pérez-Álvarez N, et al
J Antimicrob Chemother. 2013
Jan 25
Abstract |
Maraviroc Intensification of Stable Antiviral Therapy
in HIV-1-Infected Patients With Poor Immune Restoration: MARIMUNO-ANRS
145 Study.
Cuzin L,
Trabelsi S, Delobel P, et al
J Acquir Immune Defic Syndr.
2012 Dec
15;61(5):557-564.
Abstract
Maraviroc shows differential effects on glucose uptake
and lipolysis in human subcutaneous cultured adipocytes in comparison
with
omental adipocytes.
Perez-Matute P, Perez-Martinez L, et al
J Int AIDS Soc.
2012 Nov 11;15(6):18306.
Abstract
Intensification with maraviroc in HIV-infected
individuals (with or without liver cirrhosis) with a discordant CD4
response to cART.
Blanco J, Guardo A, González-Cordón A, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18384.
Abstract
Patients on a Combined Antiretroviral Therapy after
Maraviroc Clinical Test Show No Immunovirological Impairment.
Genebat M, Pulido I, Concepción Romero-Sánchez M, González-Serna A, et
al
Antiviral Res. 2012
Jun 27
Abstract
A pilot trial of adding maraviroc to suppressive antiretroviral
therapy for suboptimal CD4+ T-cell recovery
despite sustained virologic suppression: ACTG A5256.
Wilkin TJ, Lalama CM, McKinnon J,et
al
J Infect Dis.
2012 Jun 27.
Abstract
HIV-1 Tropism Evolution after Short-Term Maraviroc
Monotherapy in HIV-1-Infected Patients.
Gonzalez-Serna A, Romero-Sánchez MC.
et al
Antimicrob Agents Chemother.
2012 Jul;56(7):3981-3
Abstract |
Responses to Switching to Maraviroc-Based Antiretroviral Therapy in
Treated Patients with
Suppressed Plasma HIV-1-RNA Load.
Vitiello P, Brudney D, Maccartney M,
et al
Intervirology.
2012;55(2):172-8
Abstract |
Lack of short-term increase in serum mediators of fibrogenesis and in
non-invasive markers of liver fibrosis in
HIV/hepatitis C virus-coinfected patients starting maraviroc-based
antiretroviral therapy.
Macías J, Viloria MM, Rivero A, et al
Eur J Clin Microbiol Infect Dis. 2012
Jan 19.
Abstract |
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted
by
blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R
with
aprepitant, an FDA approved anti-nausea drug.
Kast RE.
J Clin Pharm Ther.
2010 Dec;35(6):657-63.
Abstract |
Clinical outcome in resistant HIV-2 infection treated with
raltegravir and maraviroc.
Armstrong-James D, Stebbing J, Scourfield A, et al
Antiviral Res. 2010 Mar 4.
Abstract |
Raltegravir, maraviroc, etravirine: an effective protease inhibitor
and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in
HIV-infected patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A, et al
A IDS. 2010 Feb 11
Abstract |
|
| |
PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING
REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM)
(HPTN 069/ACTG A5305).
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, et al
J Infect Dis. 2016
Nov 2.
Abstract
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of
Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Fox J, Tiraboschi JM, Herrera C,
et al
J Acquir Immune Defic Syndr.
2016 Nov 1;73(3):252-257.
Abstract
Pharmacokinetic/pharmacodynamic investigation of single dose oral
maraviroc in the context of HIV-1 pre exposure prophylaxis (PrEP).
Fox J, Tiraboschi JM, Herrera C,
et al
J Acquir Immune Defic Syndr.
2016
Abstract
Maraviroc and reverse transcriptase inhibitors combinations
as potential pre-exposure prophylaxis candidates.
Herrera C, Armanasco N, García-Pérez J, et al
AIDS. 2016 Feb 6
Abstract
Pharmacodynamic Activity of Dapivirine and Maraviroc Single
Entity and Combination Topical Gels for HIV-1 Prevention.
Dezzutti CS, Yandura S, Wang L,
et al
Pharm Res.
2015 Jun 16.
Abstract
Protection against re in macaques by rectal specific-gel formulations of
maraviroc and tenofovir.ctal
SHIV transmission
Dobard CW, Taylor A, Sharma S,
et al
Infect Dis. 2015 Jun 12
Abstract
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of
Dapivirine and Maraviroc Vaginal Rings: a Double-Blind Randomized Trial.
Chen BA, Panther L, Marzinke MA, et al
J Acquir Immune Defic Syndr.
2015 May 28.
Abstract
Triple combination of carbosilane dendrimers, tenofovir and maraviroc
as potential microbicide to prevent HIV-1 sexual transmission.
Sepúlveda-Crespo D, Sánchez-Rodríguez J,
Nanomedicine (Lond). 2015
Mar;10(6):899-914.
Abstract
Oral CCR5 Inhibitors to Prevent HIV Transmission: The New "Morning-Before
Pill"?
Piguet V.
J Invest Dermatol. 2013
Dec;133(12):2662-3.
Abstract
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in
primary cells: implications for treatment and prevention.
Latinovic O, Le N, Reitz M, Pal R,
et al
AIDS. 2011 Jun 1;25(9):1232-5.
Abstract
|
|
Maraviroc
Journal Citations |
|
Animal
Studies
Documents
identified with this icon are in Portable Document Format (PDF) and require the